Business Summary
MIMEDX Group, Inc. (MDXG) is a pioneer in advanced wound care and surgical biologics, focused on placental-tissue allografts and related products that enable healing of chronic and hard-to-heal wounds. The company has nearly two decades of experience manufacturing human-derived products from donated birth tissue (placental membrane, umbilical cord, and placental disc) through its proprietary PURION processing technology. Since 2024, MIMEDX has broadened beyond its placental allograft roots to add xenografts and third-party distributed wound care products, positioning itself as a multi-modality advanced wound care platform.
Products & Services
- EPIFIX — amniotic membrane allograft; flagship wound care product, room-temperature storage, 5-year shelf life; used for DFUs, VLUs, pressure ulcers
- EPICORD / EPICORD Expandable — umbilical cord-derived allograft for larger, deeper wounds
- EPIEFFECT — placental tissue allograft; RCT in progress for expanded private payer coverage
- EPIXPRESS — new allograft launched late 2025
- **AMNIOFIX...
AI-generated summary of Item 1 (Business) from the 10-K filed Feb 25, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q2 2026| Largest holders | Reported value |
|---|---|
| Essex Woodlands Management Inc | $108.6M |
| BlackRock Inc | $46.8M |
| Trigran Investments Inc | $27.6M |
| STATE STREET CORPORATION | $21.5M |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.0M |
Funds & ETFs · N-PORT
Insider trades · Form 4
Annual results · 10-K
Fiscal 2025- Revenue
- $418.6M
- Net income
- $48.6M
As reported in the fiscal 2025 annual report.
Federal lobbying · LD-2
Securities
| CUSIP | Security | Type |
|---|---|---|
| 602496101 | MDXG MIMEDX GROUP INC | Common stock |